Tawfik Abdulrahman, Alzahrani Abdulrahman, Alharbi Sami, Almitairi Jamal, Alzahrani Arwa, Alshehri Mohammed Ali, Aldughaim Mohammed S, Alothaid Hani
Medical Cluster of Infection Prevention and Control, Alqassim, Saudi Arabia.
Department of Applied Medical Sciences, Applied College, Al Baha University, Al-Baha, Saudi Arabia.
Adv Virol. 2022 Jun 29;2022:9240941. doi: 10.1155/2022/9240941. eCollection 2022.
COVID-19 is a disease caused by a novel coronavirus with no specific, standard treatment. We investigated the clinical data of COVID-19 patients admitted to King Fahad Specialist Hospital (KFSH) in Buraydah by comparing the patients who were treated early with favipiravir (within 3 days of admission) to patients who were treated after three days of admission or not treated. 165 patients were confirmed with PCR tests and admitted to KFSH for treatment. Comorbidities contributed significantly to increasing the length of stay in hospital at 11.4 ± 0.8 days compared to patients with no comorbidities at 8.6 ± 0.9 days (=0.041). A total of 103 patients were treated with favipiravir, and we found that early treatment with favipiravir (within 3 days) reduced the length of stay in hospital significantly (8.8 ± 1.4 days) compared to patients who were treated after 3 days (13.3 ± 4.6 days) (=0.0015). Moreover, patients with comorbidities in both early and late treatment groups had significantly higher average lengths of stay in hospital (11.2 ± 0.9 days) compared to patients with no comorbidities (7.9 ± 0.7 days) (=0.017). Interestingly, patients treated early with favipiravir (with comorbidities and without) stayed fewer days in hospital compared to those with late treatment (=0.021; a difference of 4.5 ± 1.9 days; and =0.018; a difference of 4.2 ± 1.7 days, respectively). In conclusion, our analysis indicates that early treatment with favipiravir can reduce the length of stay in hospital and improve clinical manifestations of COVID-19 patients.
新冠病毒肺炎（COVID - 19）是一种由新型冠状病毒引起的疾病，目前尚无特效的标准治疗方法。我们通过比较在布赖代法赫德国王专科医院（KFSH）住院的COVID - 19患者的临床数据，将入院3天内早期接受法匹拉韦治疗的患者与入院3天后接受治疗或未接受治疗的患者进行了对比。165名患者经聚合酶链反应（PCR）检测确诊后入住KFSH接受治疗。合并症显著延长了住院时间，合并症患者的住院时间为11.4±0.8天，而无合并症患者为8.6±0.9天（P = 0.041）。共有103名患者接受了法匹拉韦治疗，我们发现，与3天后接受治疗的患者（13.3±4.6天）相比，早期（3天内）使用法匹拉韦治疗可显著缩短住院时间（8.8±1.4天）（P = 0.0015）。此外，早期和晚期治疗组中合并症患者的平均住院时间（11.2±0.9天）均显著高于无合并症患者（7.9±0.7天）（P = 0.017）。有趣的是，早期接受法匹拉韦治疗的患者（无论有无合并症）住院天数均少于晚期治疗的患者（P = 0.021；差异为4.5±1.9天；P = 0.018；差异为4.2±1.7天）。总之，我们的分析表明，早期使用法匹拉韦治疗可缩短COVID - 19患者的住院时间并改善临床表现。
